InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Operating Leases of $30766.0 for Q1 2026, down 92.66% year-over-year from $419347.0 in Q1 2025, and down 75.15% quarter-over-quarter from $123827.0 in Q4 2025.
InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $30766.0 for Q1 2026.
- In Q1 2026, Operating Leases fell 92.66% year-over-year to $30766.0; the TTM figure through Mar 2026 stood at $30766.0 (down 92.66% YoY), while the FY2025 annual figure was $305755.0, down 52.59% from the prior year.
- Operating Leases for Q1 2026 stood at $30766.0, down from $123827.0 in the prior quarter.
- The five-year high for Operating Leases was $1.1 million in Q3 2024, with the low at $15994.0 in Q2 2023.
- The 5-year median for Operating Leases is $305755.0 (2025), against an average of $388143.2.
- The sharpest annual moves came in 2023 and 2024: Operating Leases plunged 95.89% in 2023, then soared 3931.92% in 2024.
- InMed Pharmaceuticals' Operating Leases stood at $183902.0 in 2022, then soared by 336.53% to $802784.0 in 2023, then sank by 34.07% to $529248.0 in 2024, then sank by 76.6% to $123827.0 in 2025, then tumbled by 75.15% to $30766.0 in 2026.
- Business Quant data shows INM's Operating Leases at $30766.0 in Q1 2026, $123827.0 in Q4 2025, and $215478.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,766.00 |
| Dec 31, 2025 | 123,827.00 |
| Sep 30, 2025 | 215,478.00 |
| Jun 30, 2025 | 305,755.00 |
| Mar 31, 2025 | 419,347.00 |
| Dec 31, 2024 | 529,248.00 |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 644,865.00 |
| Mar 31, 2024 | 725,236.00 |
| Dec 31, 2023 | 802,784.00 |
| Sep 30, 2023 | 292,998.00 |
| Jun 30, 2023 | 15,994.00 |
| Mar 31, 2023 | 72,794.00 |
| Dec 31, 2022 | 183,902.00 |
| Sep 30, 2022 | 294,337.00 |
| Jun 30, 2022 | 389,498.00 |
| Mar 31, 2022 | 493,562.00 |
| Dec 31, 2021 | 598,642.00 |
| Sep 30, 2021 | 178,591.00 |
| Jun 30, 2021 | -51,108.00 |